STOCK TITAN

NRXS Form 4: Director Grant of 13,157 Shares to Kristin Ferge

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Kristin Ferge, a director of Neuraxis, Inc. (NRXS), reported a non-derivative acquisition of common stock on 01/17/2025. She acquired 13,157 shares at a price of $2.85 per share. Following this transaction, Ms. Ferge beneficially owned 14,340 shares. The filing states these shares were issued as compensation for services rendered as an independent director of the company. The Form 4 shows the filing is made by one reporting person and includes the reporting person’s address in Carmel, IN.

Positive

  • Shares issued as director compensation align the reporting person’s interests with shareholders
  • Timely disclosure of the acquisition on Form 4 provides transparency into insider ownership changes

Negative

  • None.

Insights

TL;DR: Director received stock compensation, aligning her financial interest with shareholders without indicating material control changes.

This Form 4 documents a routine director compensation grant: 13,157 shares issued as payment for independent director services. Such equity awards are common and serve to align a director’s incentives with shareholder performance. The report shows a modest post-transaction holding of 14,340 shares, suggesting the grant represents a material portion of her reported holdings but does not by itself change governance control or signal a significant shift in insider ownership.

TL;DR: Insider acquisition via compensation is a neutral disclosure; transaction size appears routine for director pay.

The transaction is recorded as an acquisition at $2.85 per share on 01/17/2025, with shares issued rather than purchased on the open market. As a compensation issuance, this does not reflect a director-initiated market purchase and therefore is less indicative of a personal investment conviction. The disclosure is timely and provides transparency on changes in beneficial ownership.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ferge Kristin A

(Last) (First) (Middle)
11611 N. MERIDIAN ST, SUITE 330

(Street)
CARMEL IN 46032

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Neuraxis, INC [ NRXS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/17/2025 A 13,157 A $2.85(1) 14,340 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.
/s/ Kristin Ferge 09/10/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Kristin Ferge report on Form 4 for NRXS?

She reported an acquisition of 13,157 shares of Neuraxis common stock on 01/17/2025 at a price of $2.85 per share.

How many Neuraxis shares does Kristin Ferge beneficially own after the reported transaction?

Following the transaction, she beneficially owned 14,340 shares.

Why were the shares issued to Kristin Ferge?

The filing states the shares were issued as compensation for services as an independent director of the issuer.

Was the Form 4 filed by more than one reporting person?

No; the form indicates it was filed by one reporting person.

What price per share was reported for the issuance?

The reported price per share for the issuance was $2.85.
Neuraxis Inc

NYSE:NRXS

NRXS Rankings

NRXS Latest News

NRXS Latest SEC Filings

NRXS Stock Data

49.54M
8.34M
20.39%
8.55%
0.3%
Biotechnology
Electromedical & Electrotherapeutic Apparatus
Link
United States
CARMEL